Pulmatrix, Inc. (PULM) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$1.42

From 52W high−71.54%

Volume22976.00

Market cap$5.26M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$1.42

From 52W high

−71.54%

Volume

22976.00

Market cap

$5.26M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

47.2

MomentumView details →

1D Return

+0.50%

YTD Return

−34.53%

SummaryUpdated Jun 1, 2026

Pulmatrix, Inc. (NASDAQ:PULM) is a clinical-stage biotechnology company founded in 2003 and headquartered in Lexington, Massachusetts. The company went public in March 2014 and specializes in developing inhaled therapies for respiratory and other diseases with significant unmet medical needs. Pulmatrix focuses on leveraging its proprietary drug delivery platform to create innovative treatments that can be administered directly to the lungs through inhalation.

Ask drillr about Pulmatrix, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−156.94%

ROA (TTM)

−123.63%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+49.07%

FCF YoY

+51.22%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+46.18%

EBITDA YoY

+49.16%

MomentumView details →

1D Return

+0.50%

YTD Return

−34.53%

1Y Return

−70.68%

RSI (14)

47.2

vs 50D SMA

−7.09%

vs 200D SMA

−25.24%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

4.70x

Quick Ratio

4.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.29

EPS Surprise

85.50%

Beats (12Q)

4/12

Next Q EPS Est

−$2.00

Avg Surprise (4Q)

26.71%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−4.01M

Op. CF (TTM)

−3.91M

Next earningsNov 5, 2026 →

Latest newsMore news →

Pulmatrix announced its second quarter 2026 financial results and provided an update on its merger agreement with Eos SENOLYTIX, including the filing of a Form S-4.38d ago

Similar companies

Klotho Neurosciences, Inc.KLTOW Processa Pharmaceuticals, Inc.PCSA NuCana plcNCNA Galmed Pharmaceuticals Ltd.GLMD Dermata Therapeutics, Inc.DRMA Medicus Pharma Ltd.MDCXW Find similar companies →

Latest newsMore news →

Pulmatrix announced its second quarter 2026 financial results and provided an update on its merger agreement with Eos SENOLYTIX, including the filing of a Form S-4.38d ago